Confirmation

Are you sure you want to sign out?

Sign Out Cancel

Clinical Practice Guidelines
test root item
New Drug Monograph
title -v1234567-Novtest
BCEHS Handbook FAQ
About BCEHS Handbook
Licence Level Filtering

PCP ACP CCP EMR DISPATCH

Download PDF Open All

MORPHine

Classification

high alert medication

controlled and targeted substance

Opioid analgesic

Indications

ACP: Symptom relief in palliative or end-of-life patients with pain or shortness of breath

Contraindications

Known hypersensitivity to mORPHine or other opioid analgesics
Use with caution in patients with asthma, bronchospasm, or chronic obstructive pulmonary disease

Adult dosages

ACP: All indications

Requires specific training and license endorsement. Consult with palliative care team or CliniCall before selecting a dosing strategy.
0.1 mg/kg SC or
2.5-5 mg SC
May repeat every 10-30 minutes as required based on blood pressure (>100 mmHg) or as per CliniCall/palliative care team plan

Pediatric Considerations And Dosing

Not authorized

Mechanism Of Action

Acts on opioid receptors (primarily mu receptors) in the central nervous system to produce analgesia, euphoria, and sedation. Interaction with receptors in the spinal cord depresses pain transmission. Produces venodilation, reducing cardiac preload.

Pharmocokinetics

Intravenous:

Onset: rapid
Peak: 20 minutes
Half-life: 2-3 hours
Duration: 4-5 hours

Adverse Effects

Lightheadedness, dizziness, sedation, agitation
Respiratory depression and apnea
Profound hypotension
Nausea and vomiting